Scarica l'app Stockscreener
1.91
1.55%
-0.03
Dopo l'orario di chiusura:
1.90
-0.01
-0.52%
Precedente Chiudi:
$1.94
Aprire:
$1.95
Volume 24 ore:
2.64M
Relative Volume:
0.35
Capitalizzazione di mercato:
$343.97M
Reddito:
$850.00K
Utile/perdita netta:
$-68.17M
Rapporto P/E:
-4.6404
EPS:
-0.4116
Flusso di cassa netto:
$-53.29M
1 W Prestazione:
-7.73%
1M Prestazione:
-12.79%
6M Prestazione:
-70.16%
1 anno Prestazione:
-35.69%
Intervallo 1D:
$1.86
$1.96
Intervallo di 1 settimana:
$1.86
$2.225
Portata 52W:
$1.61
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Nome
Compass Therapeutics Inc
Settore
Industria
Telefono
617-500-8099
Indirizzo
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.91 | 374.58M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-13 | Iniziato | Craig Hallum | Buy |
| 2026-01-05 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Canaccord Genuity | Buy |
| 2025-12-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-01 | Ripresa | Raymond James | Outperform |
| 2025-04-02 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Iniziato | Guggenheim | Buy |
| 2025-02-19 | Iniziato | Piper Sandler | Overweight |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Iniziato | Jefferies | Buy |
| 2023-01-27 | Iniziato | Stifel | Buy |
| 2022-05-23 | Ripresa | H.C. Wainwright | Buy |
| 2022-03-15 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-01-19 | Iniziato | B. Riley Securities | Buy |
| 2021-12-22 | Iniziato | Raymond James | Outperform |
| 2021-12-20 | Iniziato | SVB Leerink | Outperform |
| 2021-12-15 | Iniziato | Wedbush | Outperform |
Mostra tutto
Compass Therapeutics Inc Borsa (CMPX) Ultime notizie
CMPX|Compass Therapeutics Inc.|Price:2.092|Chg%:+0.022 - TradingKey
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CMPX|Compass Therapeutics Inc.|Price:2.080| - TradingKey
Compass Therapeutics Inc. (CMPX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Compass Therapeutics Inc. (CMPX) Balance Sheet - TradingKey
Compass Therapeutics, Inc. Revenue Breakdown – NASDAQ:CMPX - TradingView
Compass Therapeutics Inc. (CMPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBIT forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Compass Therapeutics (CMPX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Compass Therapeutics to present Phase 2/3 tovec... - Pluang
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 - The Manila Times
Compass Therapeutics’ COMPANION-002 Biliary Tract Cancer Study Accepted for Oral Presentation at ESMO 2026 - Quiver Quantitative
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity - Seeking Alpha
Compass Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesInvestor Earnings Call - DonanımHaber
Compass Therapeutics Inc. (CMPX) Q1 2026 Earnings: Narrower-Than-Expected Loss Reinforces Clinical-Stage Focus - dars.gov.et
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Q1 2026 Earnings: Narrower-Than-Expected Loss Driven by Disciplined SpendingHigh Estimate Range - dars.gov.et
Compass Therapeutics (CMPX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
If You Invested $1,000 in Compass Therapeutics Inc (CMPX) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX) - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review
Compass Showcases Promising Tovecimig Data, Eyes Commercialization - TipRanks
Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement - TradingView
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutic - The National Law Review
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Enterprise value to revenue forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to earnings forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
$Compass Therapeutics (CMPX.US)$ - Moomoo
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings - Moomoo
Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX) - TradingView
CMPX Forecast — Price Target — Prediction for 2027 - TradingView
Compass Therapeutics (CMPX) News Flow - Moomoo
Compass Therapeutics Adopts Second Amended and Restated Bylaws - The Globe and Mail
Compass Therapeutics Q1 2026 Earnings: Narrow EPS Beat Amid No Revenue; Stock Declines SlightlyAdjusted Earnings Analysis - dars.gov.et
Compass Therapeutics Inc. (CMPX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing - Insider Monkey
Compass Therapeutics Inc Azioni (CMPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):